Navigation Links
VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
Date:11/12/2007

le inhibitor of 5-LO, which is a key enzyme in the biosynthesis of leukotrienes (important mediators of inflammation involved in the development and progression of atherosclerosis). VIA-2291 is being developed as a once-daily, oral drug to target inflammation in the blood vessel wall, thereby potentially decreasing the risk of major adverse cardiovascular events, including heart attack and stroke. According to the American Heart Association, 15.8 million patients in the U.S. have coronary artery disease.

About VIA Pharmaceuticals, Inc.

VIA Pharmaceuticals, Inc. is a biotechnology company focused on the development of compounds for the treatment of cardiovascular disease. VIA is building a pipeline of small-molecule drugs that target a significant unmet medical need: reducing inflammation in the blood vessel wall, which is an underlying cause of atherosclerosis and its complications, including heart attack and stroke. The company's lead drug candidate, VIA-2291, is in multiple Phase II clinical studies in patients with cardiovascular disease. For more information, visit: http://www.viapharmaceuticals.com.

Forward-Looking Statements

This press release may contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or to VIA's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause VIA's actual results, levels of activity, performance or achievements to be expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "continue" or the negative of these terms or other comparable terminology. You should not place undue reliance on forward-looking
'/>"/>

SOURCE VIA Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ... Company,s Chief Financial Officer has resigned.  The Company has ... Officer who retired in December 2014, as full time ... permanent successor.     Andy Ashworth began ... ensure a smooth transition.  Andy was the Company,s CFO ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... ... manufacturer and supplier, announces the launch of their 2nd generation cell therapy POD® ... current miniPOD CT, but it also represents a new POD® design. , ...
(Date:7/29/2015)... , July 29, 2015  AmnioChor Inc., an ... technology, is very pleased to announce that the Musculoskeletal ... has agreed to invest in their seed round of ... placental tissue storage capabilities. AmnioChor,s technology ... and the human stem cells living within those tissues. ...
(Date:7/29/2015)... July 29, 2015  Indivior PLC (LON: INDV) today ... nasal spray was accepted and received Priority Review by ... treatment of opioid overdose. This naloxone nasal spray comes ... for optimal absorption into the nasal mucosa. 1 ... so individuals may be better equipped to help an ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
...  Nabsys, Inc., a life sciences company pioneering development ... that data demonstrating the first direct electronic re-sequencing ... the annual Advances in Genome Biology and Technology ... Island, Fla., and the Omics and Personalized Medicine ...
... 13, 2012  Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ... 2012 Global Healthcare Conference on Wednesday, February 15, 2012.  ... The session may be accessed through the Company,s web ... page.  An archived version of the presentation will be ...
... Feb. 10, 2012  Neuland Laboratories Ltd., (NSE: NEULANDLAB; ... ingredients (APIs), complex intermediates and contract research and ... today announced financial results for the third quarter ... 2011. Revenues for the third ...
Cached Biology Technology:Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference 2Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference 3Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference 2Neuland Labs Reports Third Quarter Fiscal Year 2012 Financial Results 2Neuland Labs Reports Third Quarter Fiscal Year 2012 Financial Results 3
(Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
(Date:7/31/2015)... de julio de 2015 BGI llevará a cabo ... del 22 al 25 de octubre de 2015, en ... conferencia celebra su décimo aniversario este año. Desde su ... de las reuniones anuales más influyentes del mundo en ... las conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... de julho de 2015 A 10 a. ... será realizada pela BGI de 22-25 de outubro de 2015, ... A conferência está celebrando seu 10 o. aniversário ... se tornou uma das reuniões mais influentes do mundo ... mais dinâmicos, entusiastas e prazerosos. A ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... do it. Bees do it. Even environmentally stressed fish do ... of Zoology is the first in the world to discover ... His research may provide the key to the survival of ... ocean ― currently threatened by global warming. In ...
... than going it alone much longer than previously thought, according ... algae made the transition from being a single-celled organism to ... during the Triassic Period. At that time, Earth ... and early mammals. Previous estimates had suggested Volvox ,s ...
... When fruit flies mate, the females, genes are activated ... reaction starts. This is shown in a study at ... publication, Journal of Evolutionary Biology .* ... so-called microarrays, researchers at Uppsala University can show how ...
Cached Biology News:Changing sexes on the sea floor 2How Volvox got its groove 2How Volvox got its groove 3